413 related articles for article (PubMed ID: 30925904)
21. Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.
Zhou C; Che G; Zheng X; Qiu J; Xie Z; Cong Y; Pei X; Zhang H; Sun H; Ma H
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2663-2674. PubMed ID: 31541338
[TBL] [Abstract][Full Text] [Related]
22. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
[TBL] [Abstract][Full Text] [Related]
23. Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma.
Hu W; Lu SX; Li M; Zhang C; Liu LL; Fu J; Jin JT; Luo RZ; Zhang CZ; Yun JP
Oncotarget; 2015 Mar; 6(9):6570-83. PubMed ID: 25788265
[TBL] [Abstract][Full Text] [Related]
24. Up-regulation of PKM2 promote malignancy and related to adverse prognostic risk factor in human gallbladder cancer.
Lu W; Cao Y; Zhang Y; Li S; Gao J; Wang XA; Mu J; Hu YP; Jiang L; Dong P; Gong W; Liu Y
Sci Rep; 2016 Jun; 6():26351. PubMed ID: 27283076
[TBL] [Abstract][Full Text] [Related]
25. Prognostic implications of programmed death ligand 1 expression in resected lung adenocarcinoma: a systematic review and meta-analysis.
Chen D; Mao Y; Ding Q; Wang W; Zhu F; Chen C; Chen Y
Eur J Cardiothorac Surg; 2020 Nov; 58(5):888-898. PubMed ID: 32596715
[TBL] [Abstract][Full Text] [Related]
26. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
27. The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma.
Wu S; Shi X; Sun J; Liu Y; Luo Y; Liang Z; Wang J; Zeng X
Oncotarget; 2017 Mar; 8(10):16421-16429. PubMed ID: 28145884
[TBL] [Abstract][Full Text] [Related]
28. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
Larsen TV; Hussmann D; Nielsen AL
Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
[TBL] [Abstract][Full Text] [Related]
29. Clinical importance of VEGFC and PD-L1 co-expression in lung adenocarcinoma patients.
Qin T; Xia J; Liu S; Wang J; Liu H; Zhang Y; Jia Y; Li K
Thorac Cancer; 2020 May; 11(5):1139-1148. PubMed ID: 32154654
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients.
Takamori S; Takada K; Azuma K; Jogo T; Shimokawa M; Toyokawa G; Hirai F; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
Ann Surg Oncol; 2019 Jun; 26(6):1916-1924. PubMed ID: 30815801
[TBL] [Abstract][Full Text] [Related]
31. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
Takada K; Okamoto T; Shoji F; Shimokawa M; Akamine T; Takamori S; Katsura M; Suzuki Y; Fujishita T; Toyokawa G; Morodomi Y; Okano S; Oda Y; Maehara Y
J Thorac Oncol; 2016 Nov; 11(11):1879-1890. PubMed ID: 27346415
[TBL] [Abstract][Full Text] [Related]
32. High expression of PKM2 synergizes with PD-L1 in tumor cells and immune cells to predict worse survival in human lung adenocarcinoma.
Long L; Chen M; Yuan Y; Ming AL; Guo W; Wu K; Chen H
J Cancer; 2020; 11(15):4442-4452. PubMed ID: 32489463
[No Abstract] [Full Text] [Related]
33. Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma.
Song Z; Yu X; Zhang Y
Lung Cancer; 2016 Sep; 99():166-71. PubMed ID: 27565935
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.
Zhu J; Wen H; Bi R; Wu Y; Wu X
J Gynecol Oncol; 2017 Nov; 28(6):e77. PubMed ID: 29027395
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
36. Upregulation of PD-L1 predicts poor prognosis and is associated with miR-191-5p dysregulation in colon adenocarcinoma.
Chen XY; Zhang J; Hou LD; Zhang R; Chen W; Fan HN; Huang YX; Liu H; Zhu JS
Int J Immunopathol Pharmacol; 2018; 32():2058738418790318. PubMed ID: 30045644
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-147b promotes lung adenocarcinoma cell aggressiveness through negatively regulating microfibril-associated glycoprotein 4 (MFAP4) and affects prognosis of lung adenocarcinoma patients.
Feng YY; Liu CH; Xue Y; Chen YY; Wang YL; Wu XZ
Gene; 2020 Mar; 730():144316. PubMed ID: 31884109
[TBL] [Abstract][Full Text] [Related]
38. Down-regulation of RCC1 sensitizes immunotherapy by up-regulating PD-L1 via p27
Zeng X; Zhong M; Yang Y; Wang Z; Zhu Y
J Cell Mol Med; 2021 Apr; 25(8):4136-4147. PubMed ID: 33630417
[TBL] [Abstract][Full Text] [Related]
39. 2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma.
Kaira K; Shimizu K; Kitahara S; Yajima T; Atsumi J; Kosaka T; Ohtaki Y; Higuchi T; Oyama T; Asao T; Mogi A
Eur J Cancer; 2018 Sep; 101():181-190. PubMed ID: 30077123
[TBL] [Abstract][Full Text] [Related]
40. Silencing of Perilipin 3 Inhibits Lung Adenocarcinoma Cell Immune Resistance by Regulating the Transcription of PD-L1 Through c-Myc.
Men X; Zhu W
Immunol Invest; 2023 Nov; 52(7):815-831. PubMed ID: 37578465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
